Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing`s Syndrome


An Open-label Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing`s Syndrome




Patients will receive Corlux (mifepristone) daily for up to 24 weeks. Assessments of the signs and symptoms of Cushing`s syndrome will be obtained.

Study Status: Completed


Condition Intervention Phase
Cushing`s Syndrome Drug: mifepristone Phase 3

Verified by Corcept Therapeutics August, 2013

Sponsored by: Corcept Therapeutics
Information provided by: Corcept Therapeutics identifier: NCT00569582

Study Type: Interventional

Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Foundation; Dept of Endocrinology, Diabetes & Metabolism
Cleveland, Ohio 44195
United States

Coleman Gross., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site